Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Galena Biopharma GALE

"Galena Biopharma is a biopharmaceutical company. Its main activity is the development and commercialization of hematology and oncology therapies. Its pipeline includes products targeting hematology diseases, breast cancer, gastric cancer, and gynecological cancer. The company’s cancer immunotherapy consists of two areas: prevention of cancer reoccurrence and primary prevention of invasive breast cancer."


NDAQ:GALE - Post by User

Post by MissionIRon Feb 04, 2014 3:01pm
116 Views
Post# 22171181

Galena Biopharma, Inc. (GALE) Presenting at 16th Annual BIO

Galena Biopharma, Inc. (GALE) Presenting at 16th Annual BIO

Galena Biopharma, Inc. (GALE) Presenting at 16th Annual BIO CEO & Investor Conference

Galena Biopharma, a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, says it will be presenting at the 16th Annual BIO CEO & Investor Conference next week in New York City. The company’s President and Chief Executive Officer, Mark J. Anh, Ph.D. will deliver a corporate update at the conference on Monday, February 10, 2014 at 9:00 am EST.

The conference is taking place at the Waldorf Astoria Hotel in New York City, New York. Those who wish to see the presentation are advised to visit the Investors section of Galena Biopharma’s website: https://investors.galenabiopharma.com.

Recently, Galena Biopharma’s share price rose from $5.00 on December 31, 2013 to over $7.00 in the past three weeks. That, say analysts, stems from the positive news that has been emerging concerning the biopharmaceutical company’s oncology treatments.

More information about Galena Biopharma and its growth potential can be found at: www.galenabiopharma.com

Please read full disclaimers at https://disclaimer.missionir.com

<< Previous
Bullboard Posts
Next >>